Literature DB >> 7799346

Systemic disease in subacute cutaneous lupus erythematosus: a controlled comparison with systemic lupus erythematosus.

M R Cohen1, D Crosby.   

Abstract

OBJECTIVE: We sought to compare the prevalence of systemic disease in subacute cutaneous lupus erythematosus (SCLE) with systemic lupus erythematosus (SLE).
METHODS: Clinical and laboratory features of 14 patients with SCLE were compared with 22 age and sex matched controls with SLE.
RESULTS: Manifestations other than arthritis and skin disease were present in 11/14 (79%) SCLE cases compared with 19/22 (82%) SLE cases. Severe systemic disease occurred in one-half of patients with SCLE (5/7 men, 1/7 women), and most had the papulosquamous pattern.
CONCLUSION: Systemic manifestations may be as varied in SCLE as in SLE, and severe disease is not unusual. In particular, men with papulosquamous SCLE may be at higher risk for severe extracutaneous disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7799346

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  5 in total

1.  Using the American College of Rheumatology (ACR) and Systemic Lupus International Collaborating Clinics (SLICC) criteria to determine the diagnosis of systemic lupus erythematosus (SLE) in patients with subacute cutaneous lupus erythematosus (SCLE).

Authors:  Janice Tiao; Rui Feng; Kasey Carr; Joyce Okawa; Victoria P Werth
Journal:  J Am Acad Dermatol       Date:  2016-02-18       Impact factor: 11.527

2.  Treatment of Cutaneous Lupus Erythematosus: Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence-based Medicine Criteria.

Authors:  R R Winkelmann; Grace K Kim; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2013-01

3.  Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients.

Authors:  Siamak Moghadam-Kia; Katherine Chilek; Elizabeth Gaines; Melissa Costner; Mathew E Rose; Joyce Okawa; Victoria P Werth
Journal:  Arch Dermatol       Date:  2009-03

Review 4.  Cutaneous lupus erythematosus: diagnosis and treatment.

Authors:  L G Okon; V P Werth
Journal:  Best Pract Res Clin Rheumatol       Date:  2013-06       Impact factor: 4.098

5.  Effect of in vivo Hydroxychloroquine and ex vivo Anti-BDCA2 mAb Treatment on pDC IFNα Production From Patients Affected With Cutaneous Lupus Erythematosus.

Authors:  Agnes Gardet; Alex Pellerin; Christie-Ann McCarl; Rohan Diwanji; Wenting Wang; Douglas Donaldson; Nathalie Franchimont; Victoria P Werth; Dania Rabah
Journal:  Front Immunol       Date:  2019-02-21       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.